| Structure |
Catalog |
Product Name |
CAS |
E3 Ligase |
Target |
Inquiry |
![N-(35-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18,21,24,27,30,33-undecaoxapentatriacontyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide](https://resource.bocsci.com/structure/2267291-00-7.gif) |
BPL-202673 |
N-(35-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18,21,24,27,30,33-undecaoxapentatriacontyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide |
2267291-00-7 |
CRBN |
Tau |
Inquiry |
|
Molecular Weight: 1023.15
Molecular Formula: C51H70N6O16
Boiling Point: 1096.9±65.0°C at 760 Torr
Density: 1.284±0.06 g/cm3
Description: It is a Tau-targeted protein degrader enabled by patient-induced pluripotent stem cells-derived euronal models of tauopathy.
|
![N-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide](https://resource.bocsci.com/structure/2267290-93-5.gif) |
BPL-202674 |
N-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide |
2267290-93-5 |
CRBN |
Tau |
Inquiry |
|
Molecular Weight: 594.67
Molecular Formula: C33H34N6O5
Boiling Point: 963.9±65.0°C at 760 Torr
Density: 1.384±0.06 g/cm3
Description: It is a Tau-targeted protein degrader enabled by patient-induced pluripotent stem cells-derived euronal models of tauopathy.
|
![N-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)ethyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide](https://resource.bocsci.com/structure/2267291-14-3.gif) |
BPL-202675 |
N-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)ethyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide |
2267291-14-3 |
CRBN |
Tau |
Inquiry |
|
Molecular Weight: 627.65
Molecular Formula: C33H33N5O8
Boiling Point: 954.5±65.0°C at 760 Torr
Density: 1.404±0.06 g/cm3
Description: It is a Tau-targeted protein degrader enabled by patient-induced pluripotent stem cells-derived euronal models of tauopathy.
|
![N-(2-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)ethoxy)ethyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide](https://resource.bocsci.com/structure/2267291-16-5.gif) |
BPL-202676 |
N-(2-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)ethoxy)ethyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide |
2267291-16-5 |
CRBN |
Tau |
Inquiry |
|
Molecular Weight: 671.71
Molecular Formula: C35H37N5O9
Boiling Point: 964.8±65.0°C at 760 Torr
Density: 1.381±0.06 g/cm3
Description: It is a Tau-targeted protein degrader enabled by patient-induced pluripotent stem cells-derived euronal models of tauopathy.
|
![N-(14-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-3,6,9,12-tetraoxatetradecyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide](https://resource.bocsci.com/structure/2267291-17-6.gif) |
BPL-202677 |
N-(14-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-3,6,9,12-tetraoxatetradecyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide |
2267291-17-6 |
CRBN |
Tau |
Inquiry |
|
Molecular Weight: 715.76
Molecular Formula: C37H41N5O10
Boiling Point: 976.7±65.0°C at 760 Torr
Density: 1.361±0.06 g/cm3
Description: It is a Tau-targeted protein degrader enabled by patient-induced pluripotent stem cells-derived euronal models of tauopathy.
|
![N-(5-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide](https://resource.bocsci.com/structure/2267291-18-7.gif) |
BPL-202678 |
N-(5-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide |
2267291-18-7 |
CRBN |
Tau |
Inquiry |
|
Molecular Weight: 581.63
Molecular Formula: C32H31N5O6
Boiling Point: 939.2±65.0°C at 760 Torr
Density: 1.392±0.06 g/cm3
Description: It is a Tau-targeted protein degrader enabled by patient-induced pluripotent stem cells-derived euronal models of tauopathy.
|
![N-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide](https://resource.bocsci.com/structure/2267291-15-4.gif) |
BPL-202679 |
N-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide |
2267291-15-4 |
CRBN |
Tau |
Inquiry |
|
Molecular Weight: 595.66
Molecular Formula: C33H33N5O6
Boiling Point: 939.8±65.0°C at 760 Torr
Density: 1.371±0.06 g/cm3
Description: It is a Tau-targeted protein degrader enabled by patient-induced pluripotent stem cells-derived euronal models of tauopathy.
|
![(2S,4R)-1-((S)-2-(tert-Butyl)-4,14-dioxo-16-(5H-pyrido[4,3-b]indol-7-yl)-7,10-dioxa-3,13-diazahexadecanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/2267291-01-8.gif) |
BPL-202680 |
(2S,4R)-1-((S)-2-(tert-Butyl)-4,14-dioxo-16-(5H-pyrido[4,3-b]indol-7-yl)-7,10-dioxa-3,13-diazahexadecanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide |
2267291-01-8 |
VHL |
Tau |
Inquiry |
|
Molecular Weight: 826.03
Molecular Formula: C44H55N7O7S
Boiling Point: 1116.6±65.0°C at 760 Torr
Density: 1.276±0.06 g/cm3
Description: It is a Tau-targeted protein degrader enabled by patient-induced pluripotent stem cells-derived euronal models of tauopathy.
|
![(2S,4R)-1-((S)-2-(tert-Butyl)-4,20-dioxo-22-(5H-pyrido[4,3-b]indol-7-yl)-7,10,13,16-tetraoxa-3,19-diazadocosanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/2267291-03-0.gif) |
BPL-202681 |
(2S,4R)-1-((S)-2-(tert-Butyl)-4,20-dioxo-22-(5H-pyrido[4,3-b]indol-7-yl)-7,10,13,16-tetraoxa-3,19-diazadocosanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide |
2267291-03-0 |
VHL |
Tau |
Inquiry |
|
Molecular Weight: 914.14
Molecular Formula: C48H63N7O9S
Boiling Point: 1149.9±65.0°C at 760 Torr
Density: 1.259±0.06 g/cm3
Description: It is a Tau-targeted protein degrader enabled by patient-induced pluripotent stem cells-derived euronal models of tauopathy.
|
![(2S,4R)-1-((S)-2-(tert-Butyl)-4,26-dioxo-28-(5H-pyrido[4,3-b]indol-7-yl)-7,10,13,16,19,22-hexaoxa-3,25-diazaoctacosanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/2267291-04-1.gif) |
BPL-202682 |
(2S,4R)-1-((S)-2-(tert-Butyl)-4,26-dioxo-28-(5H-pyrido[4,3-b]indol-7-yl)-7,10,13,16,19,22-hexaoxa-3,25-diazaoctacosanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide |
2267291-04-1 |
VHL |
Tau |
Inquiry |
|
Molecular Weight: 1002.24
Molecular Formula: C52H71N7O11S
Boiling Point: 1177.3±65.0°C at 760 Torr
Density: 1.245±0.06 g/cm3
Description: It is a Tau-targeted protein degrader enabled by patient-induced pluripotent stem cells-derived euronal models of tauopathy.
|
![(2S,4R)-1-((S)-2-(8-(3-(5H-Pyrido[4,3-b]indol-7-yl)propanamido)octanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/2267291-05-2.gif) |
BPL-202683 |
(2S,4R)-1-((S)-2-(8-(3-(5H-Pyrido[4,3-b]indol-7-yl)propanamido)octanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide |
2267291-05-2 |
VHL |
Tau |
Inquiry |
|
Molecular Weight: 808.06
Molecular Formula: C45H57N7O5S
Boiling Point: 1098.3±65.0°C at 760 Torr
Density: 1.241±0.06 g/cm3
Description: It is a Tau-targeted protein degrader enabled by patient-induced pluripotent stem cells-derived euronal models of tauopathy.
|
 |
BPL-202684 |
PPC5 |
2471969-10-3 |
VHL |
BCL-xL
BCL2 |
Inquiry |
|
Molecular Weight: 1599.44
Molecular Formula: C79H99ClF3N11O11S4
Density: 1.41±0.1 g/cm3
Description: It is a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
|
 |
BPL-202685 |
PPC6 |
2471969-13-6 |
VHL |
BCL-xL
BCL2 |
Inquiry |
|
Molecular Weight: 1613.47
Molecular Formula: C80H101ClF3N11O11S4
Density: 1.40±0.1 g/cm3
Description: It is a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
|
 |
BPL-202686 |
PPC7 |
2471969-14-7 |
VHL |
BCL2
BCL-xL |
Inquiry |
|
Molecular Weight: 1627.47
Molecular Formula: C81H103ClF3N11O11S4
Density: 1.39±0.1 g/cm3
Description: It is a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
|
 |
BPL-202687 |
PPC8 |
2471969-16-9 |
VHL |
BCL2
BCL-xL |
Inquiry |
|
Molecular Weight: 1641.52
Molecular Formula: C82H105ClF3N11O11S4
Density: 1.39±0.1 g/cm3
Description: It is a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
|
 |
BPL-202688 |
PPC9 |
2471969-19-2 |
VHL |
BCL2
BCL-xL |
Inquiry |
|
Molecular Weight: 1655.55
Molecular Formula: C83H107ClF3N11O11S4
Density: 1.38±0.1 g/cm3
Description: It is a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
|
 |
BPL-202689 |
PPC10 |
2471969-22-7 |
VHL |
BCL2
BCL-xL |
Inquiry |
|
Molecular Weight: 1669.58
Molecular Formula: C84H109ClF3N11O11S4
Density: 1.37±0.1 g/cm3
Description: It is a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
|
 |
BPL-202690 |
PPC11 |
2471969-24-9 |
VHL |
BCL2
BCL-xL |
Inquiry |
|
Molecular Weight: 1683.59
Molecular Formula: C85H111ClF3N11O11S4
Density: 1.37±0.1 g/cm3
Description: It is a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
|
 |
BPL-202691 |
753a |
2471970-59-7 |
VHL |
BCL2
BCL-xL |
Inquiry |
|
Molecular Weight: 1641.52
Molecular Formula: C82H105ClF3N11O11S4
Density: 1.39±0.1 g/cm3
Description: It is a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
|
 |
BPL-202692 |
N1-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-N7-hydroxyheptanediamide |
2758388-35-9 |
CRBN |
HDAC1
HDAC3
HDAC6 |
Inquiry |
|
Molecular Weight: 416.43
Molecular Formula: C20H24N4O6
Density: 1.415±0.06 g/cm3
Description: It is an HDAC degrader with a CRBN E3 ligase ligand.
|
